Method of promoting wound healing
Disclosed is a method of promoting wound healing or wound closure. The method comprises administration of a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide. Also disclosed are method of treating chronic cutaneous wounds, method of identifying a non-healing wound, use and a pharmaceutical composition comprising a miR-198 inhibitor and/or a follistatin-like-1 (FSTL1) polypeptide.
1. A method of promoting wound healing or wound closure, wherein the method comprises administration of a miR-198 inhibitor and a follistatin-like-1 (FSTL1) polypeptide.
2. A method of treating chronic cutaneous wounds, wherein the method comprises administration of a miR-198 inhibitor and a follistatin-like-1 (FSTL1) polypeptide.
3. The method of claim 1 , further comprising administration of TGF-β1 either simultaneously or before or after administration of the miR-198 inhibitor and the FSTL1 polypeptide.
4. The method of claim 1 , wherein in case miR-198 inhibitor and follistatin-like-1 (FSTL1) polypeptide are administered simultaneously or separately from each other.
5. The method of claim 2 , wherein the chronic cutaneous wounds are the wounds of a patient suffering or suspected to be suffering from diabetes mellitus.
6. The method of claim 2 , wherein the chronic cutaneous wound is diabetic ulcer.
7. The method of claim 1 , wherein administration is via systemic or topical administration.
8. The method of claim 7 , wherein administration is via topical administration.
9. The method of claim 1 , wherein the miR-198 inhibitor and FSTL1 polypeptide are administered independently of each other in an amount of between about 10 μg to 300 mg/kg body weight.
10. The method of claim 1 , wherein TGF-β1 is administered in an amount of between about 10 μg to 300 mg/kg body weight.
11. The method of claim 1 , wherein the miR-198 inhibitor is selected from the group of an anti-miR-198, peptide nucleic acid (PNA) derivatives of miR-198 inhibitor sequence and Tiny LNA anti-miRs for seed-sequence of the inhibitor.
12. The method of claim 1 , wherein the miR-198 inhibitor has the sequence: 5′-GAACCUAUCUCCCCUCUGGACC-3′ (SEQ ID NO: 1).
13. The method of claim 12 , wherein the inhibitor is unmodified.
14. The method of claim 12 , wherein the inhibitor is with at least one modification/s selected from the group consisting of 1) full or partial 2′-O-methoxy ethyl modification, 2) full or partial phosphorothioate modification, 3) cholesterol modification of 3′ end of the miR-198 inhibitor and 4) full or partial locked nucleic acid modification (LNA) of nucleotides.